So far in 2018, AstraZeneca (AZN) has seen a strong showing from its new medicines coupled with a surge in emerging market sales. Additionally, the company expects improved performance from product sales in the second half and critical news flow from its research pipeline. The company saw strong sales gains in China.
AstraZeneca has seen major recent product approvals. These approvals include Lynparza in Japan for breast cancer, Tagrisso in the EU for lung cancer, Imfinzi in Japan for unresectable stage three non-small cell lung cancer (or NSCLC), and Lokelma in the United States for hyperkalemia.
AstraZeneca (AZN) expects a number of events in the second half of fiscal 2018 associated with Lynparza, Tagrisso, Imfinzi, Farxiga, Bydureon, Bevespi, and Duaklir. The company expects a regulatory submission for Lynparza as a first-line treatment for ovarian cancer. Tagrisso was approved in Japan in August as a first-line treatment for lung cancer.
Key developments are expected for Imfinzi in the second half of the year. The company expects a regulatory decision in the EU for stage-three unresectable non-small cell lung cancer (or NSCLC). The final data readout from the MYSTIC trial and regulatory submission is expected as a first-line treatment for lung cancer. The Imfinzi data readout is also expected as a first-line treatment for head and neck cancer.
The company also expects a regulatory decision in the United States for moxetumomab pasudotox as a third-line treatment for hairy cell leukemia.
Chronic obstructive pulmonary disease (or COPD)
AstraZeneca also expects acceptance of regulatory submission in the United States for Duaklir, regulatory submission in Japan, and a regulatory decision in the EU for Bevespi for COPD.
We’ll take a look at AstraZeneca’s financial performance in the next part.